SHR-1918

Intervention

1 paper2 findings

  • 1 lab in 1 country
  • Funder: Jiangsu Hengrui Medicine
  • 2 of 2 findings with company ties
  • Human trial1

Outcomes

2

Triglyceride

downin humans1

1 study
  1. SHR-1918 decreases triglyceride in humans (-48.6% (600 mg) to -57.6% (1,200 mg) vs placebo).

    Human trialpatients with hyperlipidemia suboptimally controlled after statin run-in600 or 1,200 mg24 weeksn = 44

    Efficacy and Safety of Quarterly Dosing SHR-1918 in Patients With Suboptimally Controlled Hyperlipidemia

    JACC. Asia3 Sep 2026

More on Triglyceride

LDL-C

downin humans1

1 study
  1. SHR-1918 decreases LDL-C in humans (-18.6% (600 mg) to -22.9% (1,200 mg) vs placebo).

    Human trialpatients with hyperlipidemia suboptimally controlled after statin run-in600 or 1,200 mg24 weeksn = 44

    Efficacy and Safety of Quarterly Dosing SHR-1918 in Patients With Suboptimally Controlled Hyperlipidemia

    JACC. Asia3 Sep 2026

More on LDL-C

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 1Oct 2026: 01 in 12 months